toxylact
The first professional lActological database in the word
Prednisone (ATC A07EA03) is a locally acting intestinal corticosteroid used mainly for inflammatory bowel disease; available data suggest low breast milk transfer and generally compatible use during lactation with appropriate monitoring of the infant.atcddd.fhi+2
ATC class and general pharmacology
A07EA03 belongs to the ATC group A07 “Antidiarrheals, intestinal anti-inflammatory/anti-infective agents,” subgroup A07E “Intestinal anti-inflammatory agents” and more specifically A07EA “Corticosteroids acting locally.” Within A07EA, A07EA03 designates prednisone formulations intended to act primarily in the intestinal lumen or mucosa, typically rectal or oral preparations with limited systemic bioavailability compared with conventional systemic corticosteroids.wikipedia+1
Prednisone is a synthetic glucocorticoid prodrug that is converted hepatically to prednisolone, the active metabolite that binds glucocorticoid receptors and exerts anti‑inflammatory and immunosuppressive effects. Locally acting intestinal prednisone preparations reduce mucosal inflammation by down‑regulating pro‑inflammatory cytokines, inhibiting leukocyte migration, and stabilizing lysosomal membranes, and are used mainly in ulcerative colitis and other inflammatory bowel diseases when limited systemic exposure is desired.atcddd.fhi+2
Pharmacokinetically, conventional oral prednisone is well absorbed, undergoes first‑pass hepatic conversion to prednisolone, and is highly protein‑bound, with moderate lipid solubility and a half‑life of several hours. For A07EA03 intestinal formulations, pharmaceutical design (e.g. rectal foam, enemas, targeted oral release) aims to maximize luminal and mucosal concentrations while reducing systemic exposure, thereby potentially lowering transfer into breast milk compared with standard systemic dosing.atcddd.fhi+2
Toxicological profile
Glucocorticoids such as prednisone exhibit a characteristic toxicological profile related to dose, duration, and route of administration, including metabolic, endocrine, musculoskeletal, and immunological adverse effects. Systemic toxicity can include adrenal suppression, hyperglycemia, hypertension, fluid retention, osteoporosis, myopathy, and increased susceptibility to infection, particularly with prolonged high‑dose therapy.drugbank
For locally acting intestinal preparations (A07EA03), systemic exposure is generally reduced, and repeated‑dose toxicology studies of similar locally acting corticosteroids (e.g. budesonide in A07EA06) have shown good tolerability with minimal serious toxicity in animal models at clinically relevant doses. Nonetheless, even locally acting corticosteroids can produce systemic glucocorticoid effects, especially if used at higher doses or in patients with increased absorption due to mucosal disease or concomitant factors.accessdata.fda+1
Prednisone is not considered a classic reproductive toxin at therapeutic doses, but systemic corticosteroid exposure in pregnancy and high‑dose animal studies have been associated with fetal growth effects and malformations, underscoring the need for cautious risk–benefit evaluation. In adults, neuropsychiatric reactions (mood changes, insomnia, psychosis), gastrointestinal irritation, and dermatologic effects (skin thinning, impaired wound healing) are also recognized toxicological concerns with glucocorticoid therapy.accessdata.fda+1
Lactation pharmacology and infant exposure
Drug transfer into human milk depends on molecular weight, lipid solubility, protein binding, pKa, and half‑life, as well as maternal pharmacokinetics and dosing regimen. Glucocorticoids such as prednisone/prednisolone are moderately lipid‑soluble, partially protein‑bound, and of relatively low molecular weight, allowing diffusion into milk; however, high protein binding and limited free fraction reduce the amount excreted.samples.jbpub+1
Lactation pharmacology principles indicate that weakly basic drugs with pKa above 7.2 may undergo ion trapping in the slightly more acidic milk compartment, but the net effect on glucocorticoid milk levels is usually modest. Relative infant dose (RID), calculated as the infant’s dose through milk normalized to the maternal dose (mg/kg), is a key metric for evaluating lactation safety; RIDs below about 10% are generally considered acceptable for most medications.samples.jbpub+1
For systemic prednisone, available clinical data (summarized in lactation databases) show low concentrations of prednisolone in breast milk and RIDs typically well under the 10% threshold at standard doses, particularly when feeds are timed to avoid maternal peak plasma levels. Because A07EA03 intestinal formulations are designed to act locally and often produce lower systemic exposure than conventional oral dosing, infant exposure via milk is expected to be equal or lower than that observed with standard systemic prednisone at equivalent anti‑inflammatory effect.ncbi.nlm.nih+2
Importantly, many glucocorticoids exhibit limited oral bioavailability in infants at the small amounts present in milk, and undergo first‑pass metabolism, further reducing effective infant systemic exposure. Clinical experience and evidence‑based breastfeeding factsheets emphasize that, at usual therapeutic doses, glucocorticoids including prednisone can generally be used during breastfeeding with attention to dose, duration, and infant monitoring.ncbi.nlm.nih+3
Lactological safety assessment and clinical recommendations
General lactation safety frameworks recommend evaluating drug‑specific parameters (RID, half‑life, oral bioavailability in infants), maternal and infant clinical status, and availability of lower‑risk alternatives before classifying a medication’s compatibility with breastfeeding. For prednisone (including A07EA03 locally acting intestinal preparations), the combination of low milk levels, reduced systemic exposure with local formulations, and limited infant oral absorption supports classification as generally compatible with breastfeeding when used at standard doses.ncbi.nlm.nih+3
Evidence‑based lactation references and breastfeeding support organizations consider standard‑dose systemic glucocorticoids, including prednisone, usually acceptable, advising caution at high doses and prolonged courses and recommending timing feeds to minimize peak infant exposure when feasible. Applying these principles to A07EA03, locally acting intestinal prednisone may be preferred over more systemically bioavailable corticosteroids in breastfeeding mothers needing intestinal anti‑inflammatory therapy, provided disease control is adequate.ncbi.nlm.nih+3
Clinical recommendations include:
- Use the lowest effective dose and shortest duration of prednisone therapy consistent with disease control, favouring locally acting A07EA03 formulations in appropriate indications.atcddd.fhi+1
- Consider scheduling breastfeeding sessions immediately before maternal dosing or at least several hours after dosing to reduce infant exposure during maternal peak plasma levels, particularly with higher systemic doses.accp+1
- Monitor the breastfed infant for potential glucocorticoid‑related effects such as poor weight gain, signs of adrenal suppression (e.g. lethargy, hypotension), or increased susceptibility to infection, especially with prolonged high‑dose therapy.accp+1
- In cases requiring very high doses or long‑term systemic glucocorticoid therapy, consider individualized risk–benefit assessment, possible temporary interruption of breastfeeding, or consultation with a specialist in clinical pharmacology and lactation.accp+1
Overall, for typical A07EA03 use in inflammatory bowel disease, prednisone can be incorporated into treatment plans for breastfeeding mothers with appropriate counselling and infant surveillance, and is often preferable to uncontrolled maternal disease, which itself poses risks to both mother and child.accp+1



